Using antagonistic pleiotropy to design a chemotherapy-induced evolutionary trap to target drug resistance in cancer

[1]  C. McCall,et al.  Systematic Dissection of the Metabolic-Apoptotic Interface in AML Reveals Heme Biosynthesis to Be a Regulator of Drug Sensitivity. , 2019, Cell metabolism.

[2]  K. Rajapakshe,et al.  Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells , 2019, Blood Cancer Journal.

[3]  A. Letai,et al.  Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. , 2019, Blood.

[4]  H. Dombret,et al.  Glasdegib plus intensive/nonintensive chemotherapy in untreated acute myeloid leukemia: BRIGHT AML 1019 Phase III trials. , 2019, Future oncology.

[5]  M. Heuser,et al.  Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome , 2018, Leukemia.

[6]  E. Olejniczak,et al.  A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia. , 2018, Cancer discovery.

[7]  Lorin Crawford,et al.  Systematic mapping of BCL-2 gene dependencies in cancer reveals molecular determinants of BH3 mimetic sensitivity , 2018, Nature Communications.

[8]  Evert Bosdriesz,et al.  An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential , 2018, Cell.

[9]  C. Parmesan,et al.  Lethal trap created by adaptive evolutionary response to an exotic resource , 2018, Nature.

[10]  Joel s. Brown,et al.  The Evolution and Ecology of Resistance in Cancer Therapy. , 2018, Cold Spring Harbor perspectives in medicine.

[11]  A. López-Guillermo,et al.  The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma , 2018, Oncogene.

[12]  S. Molin,et al.  Drug-Driven Phenotypic Convergence Supports Rational Treatment Strategies of Chronic Infections , 2018, Cell.

[13]  A. Stathis,et al.  BET Proteins as Targets for Anticancer Treatment. , 2018, Cancer discovery.

[14]  Jason W. Locasale,et al.  Melanoma Therapeutic Strategies that Select against Resistance by Exploiting MYC-Driven Evolutionary Convergence. , 2017, Cell reports.

[15]  C. Swanton,et al.  Tumor Evolution as a Therapeutic Target. , 2017, Cancer discovery.

[16]  C. Vakoc,et al.  Targeting Cancer Cells with BET Bromodomain Inhibitors. , 2017, Cold Spring Harbor perspectives in medicine.

[17]  R. Margueron,et al.  Mechanisms Regulating PRC2 Recruitment and Enzymatic Activity. , 2017, Trends in biochemical sciences.

[18]  K. Bhalla,et al.  Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells , 2017, Leukemia.

[19]  J. Licht,et al.  The Role of Nuclear Receptor-Binding SET Domain Family Histone Lysine Methyltransferases in Cancer. , 2017, Cold Spring Harbor perspectives in medicine.

[20]  Brian Wood,et al.  Adobe Illustrator CC 2017 , 2017 .

[21]  B. Vick,et al.  Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia , 2016, Nature Medicine.

[22]  A. Strasser,et al.  The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models , 2016, Nature.

[23]  Wolfgang Weninger,et al.  Cell Cycle Phase-Specific Drug Resistance as an Escape Mechanism of Melanoma Cells. , 2016, The Journal of investigative dermatology.

[24]  K. Wood,et al.  Targeting MCL-1/BCL-XL Forestalls the Acquisition of Resistance to ABT-199 in Acute Myeloid Leukemia , 2016, Scientific Reports.

[25]  L. Zender,et al.  A MYC–aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer , 2016, Nature Medicine.

[26]  H. Dombret,et al.  Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study. , 2016, The Lancet. Haematology.

[27]  Raja R Srinivas,et al.  Exploiting Temporal Collateral Sensitivity in Tumor Clonal Evolution , 2016, Cell.

[28]  James E. Bradner,et al.  Response and resistance to BET bromodomain inhibitors in triple negative breast cancer , 2015, Nature.

[29]  Łukasz M. Boryń,et al.  Transcriptional plasticity promotes primary and acquired resistance to BET inhibition , 2015, Nature.

[30]  Mark A. Dawson,et al.  BET inhibitor resistance emerges from leukaemia stem cells , 2015, Nature.

[31]  C. Swanton,et al.  Can oncology recapitulate paleontology? Lessons from species extinctions , 2015, Nature Reviews Clinical Oncology.

[32]  Dolores Diaz,et al.  Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy , 2015, Science Translational Medicine.

[33]  Qiu-ying Liu,et al.  Sp1 and c-Myc modulate drug resistance of leukemia stem cells by regulating survivin expression through the ERK-MSK MAPK signaling pathway , 2015, Molecular Cancer.

[34]  M. Nykter,et al.  The Evolutionary History of Lethal Metastatic Prostate Cancer , 2015, Nature.

[35]  Andrei Kucharavy,et al.  Targeting the Adaptability of Heterogeneous Aneuploids , 2015, Cell.

[36]  Obi L. Griffith,et al.  Convergent loss of PTEN leads to clinical resistance to a PI3Kα inhibitor , 2014, Nature.

[37]  Sheng Wei,et al.  c-Myc plays part in drug resistance mediated by bone marrow stromal cells in acute myeloid leukemia. , 2015, Leukemia research.

[38]  R. Copeland,et al.  Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin Lymphomas , 2014, PloS one.

[39]  P. Tiffin,et al.  Advances and limits of using population genetics to understand local adaptation. , 2014, Trends in ecology & evolution.

[40]  P. Trojer,et al.  EZH2 inhibitor efficacy in non-Hodgkin's lymphoma does not require suppression of H3K27 monomethylation. , 2014, Chemistry & biology.

[41]  G. Evan,et al.  BIM is the primary mediator of MYC-induced apoptosis in multiple solid tissues. , 2014, Cell reports.

[42]  Quentin Liu,et al.  Inhibition of c-Myc Overcomes Cytotoxic Drug Resistance in Acute Myeloid Leukemia Cells by Promoting Differentiation , 2014, PloS one.

[43]  J. Moffat,et al.  Measuring error rates in genomic perturbation screens: gold standards for human functional genomics , 2014, bioRxiv.

[44]  Neville E. Sanjana,et al.  Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells , 2014, Science.

[45]  E. Lander,et al.  Genetic Screens in Human Cells Using the CRISPR-Cas9 System , 2013, Science.

[46]  A. McKenna,et al.  The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. , 2014, Cancer discovery.

[47]  M. Lascoux,et al.  Ecological genomics of local adaptation , 2013, Nature Reviews Genetics.

[48]  Peter Sorger,et al.  BID preferentially activates BAK while BIM preferentially activates BAX, affecting chemotherapy response. , 2013, Molecular cell.

[49]  P. Johnston,et al.  Cancer drug resistance: an evolving paradigm , 2013, Nature Reviews Cancer.

[50]  Bruce A. Robertson,et al.  Ecological novelty and the emergence of evolutionary traps. , 2013, Trends in ecology & evolution.

[51]  A. Letai,et al.  BH3 profiling in whole cells by fluorimeter or FACS. , 2013, Methods.

[52]  L. Gangoda,et al.  CREB-binding protein (CBP) regulates β-adrenoceptor (β-AR)−mediated apoptosis , 2013, Cell Death and Differentiation.

[53]  M. Cole,et al.  Molecular and Cellular Pathobiology Myc Acts via the Pten Tumor Suppressor to Elicit Autoregulation and Genome-wide Gene Repression by Activation of the Ezh2 Methyltransferase , 2022 .

[54]  A. Letai,et al.  Relative Mitochondrial Priming of Myeloblasts and Normal HSCs Determines Chemotherapeutic Success in AML , 2012, Cell.

[55]  Jonathan D. Licht,et al.  Total kinetic analysis reveals how combinatorial methylation patterns are established on lysines 27 and 36 of histone H3 , 2012, Proceedings of the National Academy of Sciences.

[56]  A. Letai,et al.  Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy , 2011, Science.

[57]  M. Campone,et al.  c-Myc dependent expression of pro-apoptotic Bim renders HER2-overexpressing breast cancer cells dependent on anti-apoptotic Mcl-1 , 2011, Molecular Cancer.

[58]  A. Bauer,et al.  Histone methylation by PRC2 is inhibited by active chromatin marks. , 2011, Molecular cell.

[59]  D. Reinberg,et al.  The Polycomb complex PRC2 and its mark in life , 2011, Nature.

[60]  Mark A. Hall,et al.  Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state. , 2010, Blood.

[61]  Huidong Shi,et al.  Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. , 2009, Blood.

[62]  C. Cass,et al.  Two distinct molecular mechanisms underlying cytarabine resistance in human leukemic cells. , 2008, Cancer research.

[63]  T. Kawecki,et al.  Conceptual issues in local adaptation , 2004 .

[64]  Andreas Villunger,et al.  p53- and Drug-Induced Apoptotic Responses Mediated by BH3-Only Proteins Puma and Noxa , 2003, Science.

[65]  P. Sherman,et al.  Ecological and evolutionary traps. , 2002 .

[66]  K. Vousden,et al.  PUMA, a novel proapoptotic gene, is induced by p53. , 2001, Molecular cell.

[67]  Jan Liliemark,et al.  Relationship of 1-β-d-Arabinofuranosylcytosine in Plasma to 1-β-d-Arabinofuranosylcytosine 5′-Triphosphate Levels in Leukemic Cells during Treatment with High-Dose 1-β-d-Arabinofuranosylcytosine , 1985 .

[68]  R. Momparler,et al.  Kinetic studies on phosphorylation of 5-azacytidine with the purified uridine-cytidine kinase from calf thymus. , 1974, Cancer research.